Core Insights - Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 11:00 a.m. ET [1] - The lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer [3] Company Overview - Aura Biosciences is headquartered in Boston, MA, and aims to grow as an innovative global oncology company that positively transforms the lives of patients [3] - The company provides a live webcast of its presentations, which will be archived for 90 days following the event [2]
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference